Critical Comparison: Veracyte (NASDAQ:VCYT) versus Curative Biotechnology (OTCMKTS:CUBTD)

Curative Biotechnology (OTCMKTS:CUBTD) and Veracyte (NASDAQ:VCYT) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, dividends, risk, profitability, institutional ownership and earnings.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Curative Biotechnology and Veracyte, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Curative Biotechnology	0	0	0	0	0.00
Veracyte	1	2	6	2	2.82

Veracyte has a consensus price target of $54.33, suggesting a potential upside of 27.75%. Given Veracyte’s stronger consensus rating and higher possible upside, analysts plainly believe Veracyte is more favorable than Curative Biotechnology.

Profitability

This table compares Curative Biotechnology and Veracyte’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Curative Biotechnology	N/A	N/A	N/A
Veracyte	20.37%	9.26%	8.61%

Risk & Volatility

Curative Biotechnology has a beta of 1.31, meaning that its share price is 31% more volatile than the S&P 500. Comparatively, Veracyte has a beta of 1.93, meaning that its share price is 93% more volatile than the S&P 500.

Valuation & Earnings

This table compares Curative Biotechnology and Veracyte”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Curative Biotechnology	N/A	N/A	N/A	N/A	N/A
Veracyte	$517.15 million	6.61	$66.35 million	$1.41	30.16

Veracyte has higher revenue and earnings than Curative Biotechnology.

Summary

Veracyte beats Curative Biotechnology on 9 of the 9 factors compared between the two stocks.

About Curative Biotechnology

Curative Biotechnology, Inc., a development-stage biomedical company, focuses on novel treatments for rare diseases. The company focuses on therapies with potentially accelerated development paths as a result of the disease, the nature of the therapeutic itself, or the stage of clinical development. Its pipeline candidates include CURB906, an antibody-drug conjugate for targeting CD56 positive brain tumors; and IMT504, a novel immune therapy to treat rabies. The company has an agreement with Mid-Atlantic BioTherapeutics, Inc. to develop the COVID-19 vaccine. Curative Biotechnology, Inc. was founded in 1995 and is based in Boca Raton, Florida.

About Veracyte

Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm’s portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA.